Patient derived glioma stem cell spheroid reporter assays for live cell high content analysis.


Journal

SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563

Informations de publication

Date de publication:
03 2023
Historique:
received: 06 08 2022
revised: 03 09 2022
accepted: 13 09 2022
pubmed: 19 9 2022
medline: 14 3 2023
entrez: 18 9 2022
Statut: ppublish

Résumé

Three dimensional models of cell culture enables researchers to recreate aspects of tumour biology not replicated by traditional two dimensional techniques. Here we describe a protocol to enable automated high throughput phenotypic profiling across panels of patient derived glioma stem cell spheroid models. We demonstrate the use of both live/dead cell end-points and monitor the dynamic changes in the cell cycle using cell lines expressing the FUCCI cell cycle reporter. Together, these assays provide additional insight into the mechanism of action of compound treatments over traditional cell viability assay endpoints.

Identifiants

pubmed: 36116760
pii: S2472-5552(22)13694-4
doi: 10.1016/j.slasd.2022.09.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-19

Subventions

Organisme : Cancer Research UK
ID : A29368
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A28596
Pays : United Kingdom

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Neil Carragher reports financial support was provided by Cancer Research UK. Neil Carragher reports financial support was provided by Brain Tumour Charity. Neil Carragher reports a relationship with Cancer Research UK that includes: funding grants and travel reimbursement.

Auteurs

Jayne Culley (J)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, UK.

Peter W Nagle (PW)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, UK; MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, Scotland, EH16 4TJ, UK.

John C Dawson (JC)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, UK.

Neil O Carragher (NO)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, UK. Electronic address: n.carragher@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH